Ann: Positive preclinical data for deoxymabs in vasculitis, page-50

“..there are doubts on whether Dr Campbell can actually do his job..”

Your statement. So I did some research as to what his qualifications and experience were and whether he presided over the only ever failed production run in the history of biotechnology research.

I clearly misunderstood the basis of your argument which appears to be that the low share price is a reflection of the markets lack of confidence in Dr. Campbell’s ability.

If this is correct then I must disagree and suggest the low share price is the product of the uncertainty created by the failed production run
and the knock on effect of pushing out the commencement of the Phase 1 trial as well as tax loss selling.

On the tax loss selling PAB is the perfect vehicle for such as the uncertainty around the current production run provides a logical reason to sell out and justifiably buy back in the new tax year if the production run is successful.

My opinion only DYOR

Fact Finder